|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RRAS |
Gene summary for RRAS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RRAS | Gene ID | 6237 |
| Gene name | RAS related | |
| Gene Alias | R-Ras | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024QZF2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6237 | RRAS | GSM4909295 | Human | Breast | IDC | 2.85e-04 | 4.06e-01 | 0.0898 |
| 6237 | RRAS | GSM4909304 | Human | Breast | IDC | 5.56e-18 | 5.02e-01 | 0.1636 |
| 6237 | RRAS | GSM4909311 | Human | Breast | IDC | 2.34e-05 | -9.98e-02 | 0.1534 |
| 6237 | RRAS | GSM4909315 | Human | Breast | IDC | 1.00e-21 | 6.95e-01 | 0.21 |
| 6237 | RRAS | GSM4909316 | Human | Breast | IDC | 2.44e-11 | 7.17e-01 | 0.21 |
| 6237 | RRAS | GSM4909319 | Human | Breast | IDC | 3.66e-07 | -5.27e-02 | 0.1563 |
| 6237 | RRAS | DCIS2 | Human | Breast | DCIS | 2.67e-45 | 1.98e-01 | 0.0085 |
| 6237 | RRAS | CA_HPV_1 | Human | Cervix | CC | 1.78e-02 | -1.49e-01 | 0.0264 |
| 6237 | RRAS | CCII_1 | Human | Cervix | CC | 3.71e-03 | -2.61e-01 | 0.3249 |
| 6237 | RRAS | Tumor | Human | Cervix | CC | 3.38e-18 | 5.06e-01 | 0.1241 |
| 6237 | RRAS | sample3 | Human | Cervix | CC | 2.98e-22 | 5.59e-01 | 0.1387 |
| 6237 | RRAS | T3 | Human | Cervix | CC | 1.77e-23 | 5.06e-01 | 0.1389 |
| 6237 | RRAS | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.31e-22 | 6.88e-01 | -0.1808 |
| 6237 | RRAS | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.70e-23 | 7.27e-01 | -0.0811 |
| 6237 | RRAS | HTA11_78_2000001011 | Human | Colorectum | AD | 4.92e-04 | 1.84e-01 | -0.1088 |
| 6237 | RRAS | HTA11_347_2000001011 | Human | Colorectum | AD | 1.17e-07 | 2.37e-01 | -0.1954 |
| 6237 | RRAS | HTA11_411_2000001011 | Human | Colorectum | SER | 3.46e-11 | 1.28e+00 | -0.2602 |
| 6237 | RRAS | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.00e-07 | 6.06e-01 | -0.2196 |
| 6237 | RRAS | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.39e-05 | 3.21e-01 | -0.1207 |
| 6237 | RRAS | HTA11_696_2000001011 | Human | Colorectum | AD | 8.08e-14 | 3.57e-01 | -0.1464 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004578514 | Breast | IDC | positive regulation of cell adhesion | 62/1434 | 437/18723 | 1.70e-06 | 7.16e-05 | 62 |
| GO:000166714 | Breast | IDC | ameboidal-type cell migration | 64/1434 | 475/18723 | 6.65e-06 | 2.05e-04 | 64 |
| GO:001063112 | Breast | IDC | epithelial cell migration | 51/1434 | 357/18723 | 1.14e-05 | 3.08e-04 | 51 |
| GO:009013212 | Breast | IDC | epithelium migration | 51/1434 | 360/18723 | 1.44e-05 | 3.70e-04 | 51 |
| GO:009013012 | Breast | IDC | tissue migration | 51/1434 | 365/18723 | 2.11e-05 | 5.11e-04 | 51 |
| GO:001063212 | Breast | IDC | regulation of epithelial cell migration | 43/1434 | 292/18723 | 2.61e-05 | 6.17e-04 | 43 |
| GO:001063413 | Breast | IDC | positive regulation of epithelial cell migration | 30/1434 | 176/18723 | 2.76e-05 | 6.50e-04 | 30 |
| GO:004354211 | Breast | IDC | endothelial cell migration | 40/1434 | 279/18723 | 8.97e-05 | 1.74e-03 | 40 |
| GO:00105951 | Breast | IDC | positive regulation of endothelial cell migration | 23/1434 | 133/18723 | 1.83e-04 | 3.07e-03 | 23 |
| GO:00512712 | Breast | IDC | negative regulation of cellular component movement | 48/1434 | 367/18723 | 1.88e-04 | 3.12e-03 | 48 |
| GO:00457651 | Breast | IDC | regulation of angiogenesis | 45/1434 | 342/18723 | 2.57e-04 | 3.98e-03 | 45 |
| GO:19013421 | Breast | IDC | regulation of vasculature development | 45/1434 | 348/18723 | 3.78e-04 | 5.38e-03 | 45 |
| GO:20001462 | Breast | IDC | negative regulation of cell motility | 46/1434 | 359/18723 | 4.01e-04 | 5.60e-03 | 46 |
| GO:00105941 | Breast | IDC | regulation of endothelial cell migration | 33/1434 | 232/18723 | 4.12e-04 | 5.66e-03 | 33 |
| GO:00703713 | Breast | IDC | ERK1 and ERK2 cascade | 43/1434 | 330/18723 | 4.28e-04 | 5.84e-03 | 43 |
| GO:00303362 | Breast | IDC | negative regulation of cell migration | 43/1434 | 344/18723 | 1.01e-03 | 1.13e-02 | 43 |
| GO:001081114 | Breast | IDC | positive regulation of cell-substrate adhesion | 20/1434 | 123/18723 | 1.05e-03 | 1.16e-02 | 20 |
| GO:00457661 | Breast | IDC | positive regulation of angiogenesis | 26/1434 | 181/18723 | 1.39e-03 | 1.43e-02 | 26 |
| GO:19040181 | Breast | IDC | positive regulation of vasculature development | 26/1434 | 181/18723 | 1.39e-03 | 1.43e-02 | 26 |
| GO:00400132 | Breast | IDC | negative regulation of locomotion | 47/1434 | 391/18723 | 1.39e-03 | 1.43e-02 | 47 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0421832 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
| hsa0413751 | Liver | HCC | Mitophagy - animal | 53/4020 | 72/8465 | 5.49e-06 | 4.59e-05 | 2.56e-05 | 53 |
| hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
| hsa0520531 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
| hsa0513230 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
| hsa0421820 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
| hsa0413728 | Oral cavity | OSCC | Mitophagy - animal | 58/3704 | 72/8465 | 1.48e-10 | 2.07e-09 | 1.05e-09 | 58 |
| hsa041409 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
| hsa046258 | Oral cavity | OSCC | C-type lectin receptor signaling pathway | 73/3704 | 104/8465 | 3.83e-08 | 3.12e-07 | 1.59e-07 | 73 |
| hsa0520526 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
| hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| hsa0481026 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
| hsa0436014 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
| hsa0401518 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
| hsa05132114 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
| hsa04218110 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
| hsa04137112 | Oral cavity | OSCC | Mitophagy - animal | 58/3704 | 72/8465 | 1.48e-10 | 2.07e-09 | 1.05e-09 | 58 |
| hsa0414014 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
| hsa0462512 | Oral cavity | OSCC | C-type lectin receptor signaling pathway | 73/3704 | 104/8465 | 3.83e-08 | 3.12e-07 | 1.59e-07 | 73 |
| hsa05205111 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RRAS | SNV | Missense_Mutation | c.382N>T | p.Arg128Trp | p.R128W | P10301 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RRAS | SNV | Missense_Mutation | c.422N>A | p.Gly141Glu | p.G141E | P10301 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RRAS | SNV | Missense_Mutation | c.173N>G | p.Tyr58Cys | p.Y58C | P10301 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A0GH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RRAS | SNV | Missense_Mutation | novel | c.566N>T | p.Ala189Val | p.A189V | P10301 | protein_coding | tolerated(0.41) | benign(0) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| RRAS | SNV | Missense_Mutation | novel | c.287N>G | p.Gln96Arg | p.Q96R | P10301 | protein_coding | tolerated(0.06) | probably_damaging(0.971) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RRAS | SNV | Missense_Mutation | rs748655822 | c.646G>A | p.Val216Ile | p.V216I | P10301 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AJ-A3OK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| RRAS | SNV | Missense_Mutation | rs747724851 | c.281G>A | p.Arg94Lys | p.R94K | P10301 | protein_coding | deleterious(0.03) | probably_damaging(0.981) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| RRAS | SNV | Missense_Mutation | novel | c.518N>T | p.Ala173Val | p.A173V | P10301 | protein_coding | deleterious(0) | possibly_damaging(0.786) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| RRAS | SNV | Missense_Mutation | c.418N>T | p.Val140Phe | p.V140F | P10301 | protein_coding | deleterious(0) | possibly_damaging(0.785) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| RRAS | SNV | Missense_Mutation | novel | c.147N>A | p.Phe49Leu | p.F49L | P10301 | protein_coding | tolerated(0.26) | probably_damaging(0.989) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |